Driven by rapid advancements in science and technology and increasing global health demands, CGT is emerging as a transformative force in biopharma. Moving from the lab to clinical applications, it is providing innovative solutions for diseases that traditional therapies struggle to address, including hereditary disorders, cancer, and rare diseases. The market is expected to reach $30.539 billion by 2025, with projections surpassing $100 billion by 2030.

Although the Chinese market is relatively new to the CGT field, it benefits from unique IIT research capabilities that are accelerating the transition of cutting-edge CGT technologies from the lab to clinical practice. The first domestically developed stem cell and gene therapies are expected to be approved and enter the market by 2025. However, CGT products are costly, with limited medical insurance coverage and relatively low patient affordability and willingness to pay. Facing challenges such as limited market size, high costs, long-term safety concerns, complex production processes, and payment difficulties, the industry must address several critical questions: How can the range of indication audience for CGT expand beyond rare diseases? How can we develop the most cost-effective CGT products through innovation and technological advancement? How can we accelerate the translation of druggable cutting-edge therapies and clinical applications? How can cooperation be accelerated to find IO Combo strategies that achieve greater-than-additive effects in treating solid tumors? How can we break into overseas markets to embrace global growth? These challenges are becoming inevitable focal points for the CGT industry as it seeks to overcome barriers and drive forward transformative advancements.

IGC is one of the earliest in-depth conventions in China dedicated to the innovation and translation of cutting-edge therapies. Over the past eight years, as the fields of immunotherapy, cell therapy, and gene therapy have grown in China, IGC 2025 will return to Beijing. This edition will kick off with six specialized forums aimed at addressing technological challenges and emerging topics of CGT, mRNA vaccines and drugs, immunotherapy antibodies and combination therapies while facilitating discussions on cutting-edge therapies, including advanced technologies, innovative therapy development, leading translations, clinical progress, and strategies for international registration. The goal is to foster deeper communication and cooperation across industry, academia, research, and medicine both domestically and internationally, accelerating the industrial translation of immunotherapies, gene therapies, and cell therapies in China.